According to Zacks, “Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. “
Separately, ValuEngine downgraded Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd.
Shares of Oncolytics Biotech stock opened at $1.61 on Tuesday. Oncolytics Biotech has a 1 year low of $1.60 and a 1 year high of $5.74. The stock has a 50-day simple moving average of $1.74. The company has a market capitalization of $32.88 million, a P/E ratio of -1.96 and a beta of 2.03. The company has a quick ratio of 3.39, a current ratio of 3.39 and a debt-to-equity ratio of 0.07.
Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, equities research analysts expect that Oncolytics Biotech will post -0.9 EPS for the current fiscal year.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Further Reading: Discover Your Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.